(Q34752319)

4 August 2017

1 reference

title

Antiadhesion molecule therapy in inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

4 August 2017

0 references

0 references

2

Paul Rutgeerts

0 references

author name string

Gert van Assche

series ordinal

1

1 reference

4 August 2017

1 July 2002

1 reference

Inflammatory Bowel Diseases

4 August 2017

1 reference

4 August 2017

8

1 reference

4 August 2017

291-300

1 reference

4 August 2017

4

1 reference

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group

4 August 2017

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

T-Cell Function and Migration — Two Sides of the Same Coin

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

A direct estimate of the human alphabeta T cell receptor diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Distinct roles of L-selectin and integrins alpha 4 beta 7 and LFA-1 in lymphocyte homing to Peyer's patch-HEV in situ: the multistep model confirmed and refined

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Critical role for β7 integrins in formation of the gut-associated lymphoid tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Molecular mechanisms of lymphocyte homing to peripheral lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Experimental Models to Study Molecular Mechanisms Underlying Intestinal Inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Adhesion molecules in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Beta2 integrin/ICAM expression in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

The coordinated action of CC chemokines in the lung orchestrates allergic inflammation and airway hyperresponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/Yit adoptive transfer model of Crohn's disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

VCAM-1 and ICAM-1 mediate leukocyte-endothelial cell adhesion in rat experimental colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1097%2F00054725-200207000-00009

10.1097/00054725-200207000-00009

21 January 2018

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12131614